Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Feedback Shares Rise 11.38% as Bleepa’s NHS Integration and National Contract Potential Lift Investor Optimism

The advance appears to reflect renewed optimism around Feedback’s discussions with NHS England concerning a potential national Bleepa contract. Management has indicated that the opportunity remains under evaluation by NHS England and HM Treasury, with the company encouraged to continue expanding the evidence base …

Ankur Sharma | 21 August 2026

Shield Therapeutics Shares Rise 11.36% as Accrufer Growth and Profitability Progress Strengthen Outlook

Shield Therapeutics is a commercial-stage pharmaceutical company focused on treating iron deficiency, with or without anaemia. Its principal product is ferric maltol, marketed as Accrufer in the United States and Feraccru across several international markets. The shares advanced after interim results showed continued prescription …

Ankur Sharma | 21 August 2026

Oxford Nanopore Technologies Shares Surge 17.75% as Clinical Momentum and Strategic Focus Revive Investor Optimism

The rally reflected a reassessment of the company’s growth quality and execution prospects. Interim results showed broad commercial progress, led by particularly encouraging demand from clinical and biopharmaceutical customers. These markets are strategically important because they could generate more repeatable workflows, deeper customer relationships …

Ankur Sharma | 21 August 2026

Faron Pharmaceuticals Shares Rise 3.70% as Bexmarilimab Data Strengthen Recovery Hopes

Faron Pharmaceuticals rose by 3.70% as investors revisited the clinical potential of bexmarilimab following an encouraging survival update from the BEXMAB study. In frontline higher-risk myelodysplastic syndrome patients without the most adverse form of TP53 mutation, median overall survival had not been reached at …

Ankur Sharma | 20 August 2026

Venture Life Group Shares Rise 3.78% as Buyback Extension and Brand Growth Strengthen Bullish Momentum

Venture Life Group rose by 3.78% after announcing an extension of its share-buyback programme. The company intends to fund additional purchases from existing cash resources and hold repurchased shares in treasury. A buyback can improve per-share metrics by reducing the effective share count and …

Ankur Sharma | 20 August 2026

Genflow Biosciences Shares Rise 3.90% as Patent Progress and SIRT6 Momentum Support Investor Optimism

Genflow Biosciences rose by 3.90% as investors continued to assess recent intellectual-property and operational developments. The company reported progress across its principal SIRT6 patent families, including publication of an American application covering the technology’s use in fatty liver disease and accelerated examination of its …

Ankur Sharma | 20 August 2026

Avacta Group Shares Rise 4.17% as Oncology Progress Reinforces Bullish Momentum

Avacta shares rose by 4.17% as investors reassessed the company’s oncology platform, maturing clinical evidence and approaching pipeline catalysts. The lead faridoxorubicin programme has demonstrated encouraging response signals in salivary gland cancer, alongside a safety profile that appears differentiated from conventional doxorubicin.

Ankur Sharma | 20 August 2026

Poolbeg Pharma Advances 3.23% as Clinical Momentum and Partnering Potential Improve Investor Sentiment

Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company focused primarily on improving the safety and accessibility of cancer immunotherapies. Its lead candidate is being studied as a preventative treatment for cytokine release syndrome, a serious inflammatory complication associated with certain immune-based cancer therapies. The …

Ankur Sharma | 20 August 2026

AOTI Stock Advances 3.08% as Medicare Coverage Prospects Drive Bullish Momentum

The 3.08% rise appears connected to continuing optimism following the proposed Local Coverage Determination issued by the Centers for Medicare & Medicaid Services. The proposal recognises topical oxygen therapy as reasonable and necessary for qualifying diabetic foot ulcers that have not responded to an …

Ankur Sharma | 20 August 2026

Why Did Genus PLC LSE:GNS Edge Higher 0.26% Amid a firmer tone across life sciences shares?

Genus PLC — LSE:GNS rose0.26% on 20 August 2026, taking the shares to 2,308.00p.

Ishan Mudgal | 20 August 2026
Support

Hi! How can we help you today?

Loading…